Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of ifn-gamma activity

摘要

The present invention relates to preventing, or treating and/or reducing the severity or progression of Type 1 immune response-mediated inflammatory lung disease. More particularly, the present invention provides a method for preventing or treating chronic obstructive pulmonary disease (COPD), severe asthma, sarcoidosis, berylliosis or cystic fibrosis by neutralizing or reducing IFNgamma bioactivity which can be achieved either by in vivo administration of IFNgamma neutralizing molecules or by in vivo immunization with pharmaceutical compositions comprising immunogenic IFNgamma proteins or IFNgamma-derived (poly)peptides or their corresponding nucleic acid sequences.